What is the prevalence of Postherpetic Neuralgia?

Postherpetic neuralgia occurs in approximately 10% to 20% of individuals who contract herpes zoster (shingles), with the prevalence increasing significantly in older populations.

Epidemiological Overview

Because Postherpetic Neuralgia is a complication of the varicella-zoster virus, its incidence is directly linked to the occurrence of shingles. While shingles is common, the transition into Postherpetic Neuralgia—defined as pain persisting for at least 90 days after the initial rash—is the clinical focus. Estimates suggest that among adults over age 60, the incidence of Postherpetic Neuralgia can rise to 30% or higher following a shingles outbreak. It is generally classified as a chronic pain syndrome rather than a rare disease in the general population, though it remains a significant burden for the geriatric community.

Demographics and Risk Factors

Age is the primary risk factor; Postherpetic Neuralgia is rare in children and young adults, with the risk escalating sharply after age 50. Data regarding gender distribution is somewhat inconsistent, though some studies suggest that women may have a slightly higher risk of developing Postherpetic Neuralgia than men. There is no strong evidence suggesting significant ethnic or geographic variations in the prevalence of the condition, as it tracks primarily with the historical prevalence of varicella-zoster infection.

Data Challenges and Real-World Insights

Accurate tracking of Postherpetic Neuralgia is hindered by inconsistent diagnostic criteria across clinical settings and the potential for under-reporting in milder cases. Many patients may manage symptoms without formal specialty consultation, leading to an underestimation of the true burden. At DiseaseMaps.org, the 48 community members currently sharing their experiences provide a vital, real-world perspective that complements clinical literature by highlighting the day-to-day impact of living with this persistent neuropathic pain, which large-scale epidemiological studies often overlook.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: The portal for rare diseases and orphan drugs


• Centers for Disease Control and Prevention (CDC) – Shingles (Herpes Zoster) Complications